CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

CD40 is essential in enabling antigen-presenting cells to process and present antigen effectively to T cells. We demonstrate here that when antibody against CD40 is used to treat mice with syngeneic lymphoma, a rapid cytotoxic T-cell response independent of T-helper cells occurs, with tenfold expansion of CD8+ T cells over a period of 5 days. This response eradicates the lymphoma and provides protection against tumor rechallenge without further antibody treatment. Thus, it seems that by treating mice with monoclonal antibody against CD40, we are immunizing against syngeneic tumors. The phenomenon proved reproducible with two antibodies against CD40 (3/23 and FGK-45) in three CD40+ lymphomas (A20, A31 and BCL1) and gave partial protection in one of two CD40– lymphomas (EL4 and Ten1). Although the nature of the target antigens on these lymphomas is unknown, CD8+ T cells recovered from responding mice showed powerful cytotoxic activity against the target B-cell lymphoma in vitro.

[1]  P. Doherty,et al.  Progressive loss of CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells , 1996, The Journal of experimental medicine.

[2]  R. Flavell,et al.  Expansion or Elimination of B Cells In Vivo: Dual Roles for CD40- and Fas (CD95)-Ligands Modulated by the B Cell Antigen Receptor , 1996, Cell.

[3]  M. Glennie,et al.  Bispecific Ab therapy of B-cell lymphoma: target cell specificity of antibody derivatives appears critical in determining therapeutic outcome , 1997, Cancer Immunology, Immunotherapy.

[4]  M. Brenner,et al.  CD40 ligand induces an antileukemia immune response in vivo. , 1997, Blood.

[5]  S. Reed,et al.  CD40 ligand is required for protective cell-mediated immunity to Leishmania major. , 1996, Immunity.

[6]  R. Flavell,et al.  CD40 and CD154 in cell-mediated immunity. , 1998, Annual review of immunology.

[7]  J. Gribben,et al.  Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. , 1997, Blood.

[8]  M. Bevan.  Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay , 1976, The Journal of experimental medicine.

[9]  D. Longo,et al.  Inhibition of human B-cell lymphoma growth by CD40 stimulation. , 1994, Blood.

[10]  C. Kurts,et al.  Brief Definitive Report Major Histocompatibility Complex Class I–restricted Cross-presentation Is Biased towards High Dose Antigens and Those Released during Cellular Destruction , 2022 .

[11]  J. Allison,et al.  CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Rolink,et al.  The SCID but Not the RAG-2 Gene Product Is Required for Sμ–Sε Heavy Chain Class Switching , 1996 .

[13]  R. Geha,et al.  Exogenous CD40 ligand induces a pulmonary inflammation response. , 1997, Journal of immunology.

[14]  A. George,et al.  Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. , 1987, Journal of immunology.

[15]  T. Kipps,et al.  Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. , 1998, The Journal of clinical investigation.

[16]  J. Gribben,et al.  CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. , 1997, The Journal of clinical investigation.

[17]  Richard A. Flavell,et al.  Help for cytotoxic-T-cell responses is mediated by CD40 signalling , 1998, Nature.

[18]  Polly Matzinger,et al.  A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell , 1998, Nature.

[19]  V. Pistoia,et al.  Production of cytokines by human B cells in health and disease. , 1997, Immunology today.

[20]  D. Fearon,et al.  Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. , 1998, Journal of immunology.

[21]  J. Gribben,et al.  Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. , 1997, Blood.

[22]  T. Horii,et al.  Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity. , 1996, Immunity.

[23]  J. Suttles,et al.  Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. , 1996, Journal of immunology.

[24]  J. Banchereau,et al.  Functions of CD40 on B cells, dendritic cells and other cells. , 1997, Current opinion in immunology.

[25]  S. Cobbold,et al.  The induction of skin graft tolerance in major histocompatibility complex‐mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti‐CD4 and anti‐CD8 antibodies , 1990, European journal of immunology.

[26]  W. Heath,et al.  Induction of a CD8+ Cytotoxic T Lymphocyte Response by Cross-priming Requires Cognate CD4+ T Cell Help , 1997, The Journal of experimental medicine.

[27]  Stephen P. Schoenberger,et al.  T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions , 1998, Nature.

[28]  A. George,et al.  Monoclonal antibodies raised against the idiotype of the murine B cell lymphoma, BCL1 act primarily with heavy chain determinants. , 1991, Hybridoma.

[29]  A. Aruffo,et al.  CD40 and its ligand, an essential ligand-receptor pair for thymus-dependent B-cell activation. , 1992, Immunology today.

[30]  E. Clark,et al.  Properties of mouse CD40: Cellular distribution of CD40 and B cell activation by monoclonal anti‐mouse CD40 antibodies , 1994, European journal of immunology.

[31]  A. Rolink,et al.  The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. , 1996, Immunity.

[32]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[33]  M. Albert,et al.  Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs , 1998, Nature.

[34]  P. Doherty,et al.  Progressive Loss of Cd8 + T Cell-mediated Control of a ~/-herpesvirus in the Absence of Cd4 + T Cells , 1996 .

[35]  J. Sun,et al.  Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. , 1996, Immunity.

[36]  R. Coffman,et al.  The induction of a protective response in Leishmania major‐infected BALB/c mice with anti‐CD40 mAb , 1998, European journal of immunology.

[37]  M. V. von Herrath,et al.  CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge , 1996, Journal of virology.

[38]  T. Boon,et al.  Tumor antigens recognized by T lymphocytes , 1997, International journal of clinical & laboratory research.

[39]  S. Burrows,et al.  Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. , 1997, Journal of immunology.

[40]  E. Morii,et al.  Involvement of transcription factor encoded by the mouse mi locus (MITF) in expression of p75 receptor of nerve growth factor in cultured mast cells of mice. , 1997, Blood.

[41]  A. Heath,et al.  Enhancement of T cell-independent immune responses in vivo by CD40 antibodies , 1998, Nature Medicine.

[42]  Loise M. Francisco,et al.  Immature Dendritic Cells Phagocytose Apoptotic Cells via αvβ5 and CD36, and Cross-present Antigens to Cytotoxic T Lymphocytes , 1998, The Journal of experimental medicine.